These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 3298467)

  • 21. Antigen presentation to cytotoxic T lymphocytes in vivo.
    Bevan MJ
    J Exp Med; 1995 Sep; 182(3):639-41. PubMed ID: 7650475
    [No Abstract]   [Full Text] [Related]  

  • 22. HLA-restricted recognition of viral antigens in HLA transgenic mice.
    Kievits F; Ivanyi P; Krimpenfort P; Berns A; Ploegh HL
    Nature; 1987 Oct 1-7; 329(6138):447-9. PubMed ID: 2821399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Class II major histocompatibility complex-restricted T cells specific for a virion structural protein that do not recognize exogenous influenza virus. Evidence that presentation of labile T cell determinants is favored by endogenous antigen synthesis.
    Eisenlohr LC; Hackett CJ
    J Exp Med; 1989 Mar; 169(3):921-31. PubMed ID: 2784481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virus-specific cytotoxic T cells in multiple sclerosis.
    McFarland HF; Goodman A; Jacobson S
    Ann N Y Acad Sci; 1988; 532():273-9. PubMed ID: 3263072
    [No Abstract]   [Full Text] [Related]  

  • 25. TAP2-defective RMA-S cells present Sendai virus antigen to cytotoxic T lymphocytes.
    Zhou X; Glas R; Momburg F; Hämmerling GJ; Jondal M; Ljunggren HG
    Eur J Immunol; 1993 Aug; 23(8):1796-801. PubMed ID: 8393798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coupling and cross-presentation.
    Heath WR; Carbone FR
    Nature; 2005 Mar; 434(7029):27-8. PubMed ID: 15744280
    [No Abstract]   [Full Text] [Related]  

  • 27. Cross priming or direct priming: is that really the question?
    Norbury CC; Sigal LJ
    Curr Opin Immunol; 2003 Feb; 15(1):82-8. PubMed ID: 12495738
    [No Abstract]   [Full Text] [Related]  

  • 28. Analysis of physical interactions between peptides and HLA molecules and application to the detection of human immunodeficiency virus 1 antigenic peptides.
    Choppin J; Martinon F; Gomard E; Bahraoui E; Connan F; Bouillot M; Lévy JP
    J Exp Med; 1990 Sep; 172(3):889-99. PubMed ID: 2388036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA class-II restriction of antigen-specific T-cell activation. With special reference to the fine specificity and immunoregulation of HLA class-II restriction elements.
    Qvigstad E; Scott H; Thorsby E
    Prog Allergy; 1985; 36():73-94. PubMed ID: 3881783
    [No Abstract]   [Full Text] [Related]  

  • 30. Endothelial cells in allograft rejection.
    Al-Lamki RS; Bradley JR; Pober JS
    Transplantation; 2008 Nov; 86(10):1340-8. PubMed ID: 19034000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen.
    Sigal LJ; Crotty S; Andino R; Rock KL
    Nature; 1999 Mar; 398(6722):77-80. PubMed ID: 10078533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of HLA antigen disparity on CML reactivity.
    Dohi K; Ono E; Fukuda Y; Asahara T; Yahata H; Ezaki H
    Hiroshima J Med Sci; 1984 Sep; 33(3):503-6. PubMed ID: 6334675
    [No Abstract]   [Full Text] [Related]  

  • 33. Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation.
    Li Y; Ke Y; Gottlieb PD; Kapp JA
    J Leukoc Biol; 1994 Nov; 56(5):616-24. PubMed ID: 7525819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanisms in evasion of host immune response by HCMV].
    Satoh T; Arase H
    Nihon Rinsho; 2006 Mar; 64 Suppl 3():421-6. PubMed ID: 16615508
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of the CD8-positive subset of T cells in proliferative responses to soluble antigens. II. CD8-positive cells are not responsible for DR-associated differences in responsiveness to mumps and Coxsackie B4.
    Bruserud O; Sollid L; Gaudernack G; Thorsby E
    Scand J Immunol; 1986 Apr; 23(4):469-73. PubMed ID: 3010444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-presenting B cells: efficient uptake and presentation by activated B cells for induction of cytotoxic T lymphocytes against vesicular stomatitis virus.
    Ciavarra RP; Burgess DH
    Cell Immunol; 1988 Jun; 114(1):27-40. PubMed ID: 2836071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How T cells see antigen.
    Grey HM; Sette A; Buus S
    Sci Am; 1989 Nov; 261(5):56-64. PubMed ID: 2530628
    [No Abstract]   [Full Text] [Related]  

  • 38. Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase.
    Del Val M; Münch K; Reddehase MJ; Koszinowski UH
    Cell; 1989 Jul; 58(2):305-15. PubMed ID: 2473842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of HLA expression in human cytomegalovirus immune evasion.
    Lin A; Xu H; Yan W
    Cell Mol Immunol; 2007 Apr; 4(2):91-8. PubMed ID: 17484802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis.
    Tanaka K; Yoshioka T; Bieberich C; Jay G
    Annu Rev Immunol; 1988; 6():359-80. PubMed ID: 3289570
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.